2023
DOI: 10.3390/antiox12030679
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Extracellular Matrix Stiffness on Candesartan Efficacy in Anti-Fibrosis and Antioxidation

Abstract: Myocardial fibrosis progression and imbalanced redox state are closely associated with increased extracellular matrix (ECM) stiffness. Candesartan (CAN), an angiotensin II (Ang II) receptor inhibitor, has shown promising anti-fibrosis and antioxidant efficacy in previous cardiovascular disease studies. However, the effect of ECM stiffness on CAN efficacy remains elusive. In this study, we constructed rat models with three different degrees of myocardial fibrosis and treated them with CAN, and then characterize… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 57 publications
(58 reference statements)
0
1
0
Order By: Relevance
“…Downstream to FAK, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), ERK1/2, NOX2, and ROS are components of the signaling cascade. The researchers elucidated, therefore, the important role of this protein activation in orchestrating cardiac fibrosis for both pro-fibrotic and oxidative stress tissue responses, as they also proved challenging the cardiac engineered tissues with the specific FAK inhibitor PF-573228 ( Zhu et al, 2023 ).…”
Section: The Shortening Gap Between Preclinical Research and Clinical...mentioning
confidence: 99%
“…Downstream to FAK, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), ERK1/2, NOX2, and ROS are components of the signaling cascade. The researchers elucidated, therefore, the important role of this protein activation in orchestrating cardiac fibrosis for both pro-fibrotic and oxidative stress tissue responses, as they also proved challenging the cardiac engineered tissues with the specific FAK inhibitor PF-573228 ( Zhu et al, 2023 ).…”
Section: The Shortening Gap Between Preclinical Research and Clinical...mentioning
confidence: 99%